Industry brief
Iran's pharmaceutical industry in 2026
Key points
- Iran makes almost all of its own medicines by count, but not the inputs. Domestic products were 98.9% of units sold in the first half of the Iranian year, while imports were still 13% of sales value.
- Market value grows mainly through prices, not volume. Unit sales rose about 1.3% year on year in the first half, while sales value reached about 400 trillion tomans.
- Currency policy is the main driver. A subsidised rate of 28,500 tomans per US dollar still applies to qualifying imports. Officials say it will not be removed this year, but the stated policy is gradual removal, and some products have already moved to the commercial rate.
- When costs rise faster than approved prices, the pressure shows up as shortages rather than price increases. In September the pharmacists' association reported about 800 products in short supply.
- Payment delays are a growing risk. Officials say many hospitals have not paid suppliers for more than a year.
1. Market size and structure
Iran's medicine market is large in local currency and small in dollars. Its nominal value grew from 10.5 trillion tomans in 1393 (2014/15) to 232.1 trillion tomans in 1403 (2024/25), a compound growth rate of about 36% a year. Volume grew only about 5.3% a year over the same period. Measured in US dollars, the market has mostly stayed in a range of 3 to 5 billion dollars, with exchange-rate shocks moving it within that range. [1]
The latest official data, from Iran's Food and Drug Administration, covers the first six months of the Iranian year 1405 (21 March to 22 September 2026): [2]
| First half of 1405 | Value (trillion tomans) | Share of value | Share of units |
|---|---|---|---|
| Domestically produced | 348 | 87% | 98.9% |
| Imported | 52 | 13% | 1.1% |
| Total | ~400 | 100% | 28.3 bn units |
Unit sales rose about 1.3% compared with the same period a year earlier. By value, the best-selling products were tirzepatide, a treatment for diabetes and weight loss (28.4 trillion tomans), insulin (12.1 trillion tomans) and saline solution (7.2 trillion tomans). By count, the top five were aspirin, atorvastatin, levothyroxine, metformin and amoxicillin. [2]
A simple doubling of the first-half figure gives about 800 trillion tomans for the full year. This is our rough annualisation, not an official forecast, and second-half prices may differ.
2. Where the inputs come from
Self-sufficiency stops at the formulation stage. Active pharmaceutical ingredients, excipients, packaging and production equipment are still largely imported. An analysis of 34 listed pharmaceutical producers found that cost of sales averages about 60% of operating revenue, and direct materials make up about 70% of that cost. [1] This is why the exchange rate matters so much to the sector.
The head of the Food and Drug Administration said in August that the 2026 conflict showed the industry still needs to reduce its dependence on imported raw materials, moving from "maximum to minimum imports". [3]
3. Currency policy: the main variable
Current rules
Qualifying medicine and medical imports still receive a subsidised rate of 28,500 tomans per US dollar, under an announcement made in April 2026. The rate does not apply to every imported medicine. [4]
Direction of travel
On 23 August 2026 the head of the Food and Drug Administration said the subsidised rate would not be removed this year, but that government policy is to remove it gradually. [3] On 3 November 2026 he said imported insulin is now allocated foreign exchange at the commercial market rate, and that higher prices for those products are therefore certain. [5]
What removal would mean
A published scenario analysis estimated the effect on the sector in 1405: [1]
| Scenario for 1405 | Sector inflation | Market size (trillion tomans) |
|---|---|---|
| Full liberalisation of the exchange rate | ~71.6% | ~873 |
| Single supported rate of 80,000 tomans | ~29.7% | ~660 |
These scenarios were published in February 2026, before the conflict. They are useful for direction, not as current estimates.
4. Shortages and prices
The core mechanism is simple. Prices are set administratively. When the cost of inputs rises and approved prices are not adjusted at the same time, producers and importers supply less. The shock appears as shortages rather than as higher prices.
- In September 2026 a spokesman for the Iranian Pharmacists Association said about 800 products were in short supply, including about 90 essential or life-saving medicines. About half of the 800 were domestically made. [6]
- In late August the same association estimated that medicine prices had risen by about 80% on average since March, with some products up 300%. This is the association's assessment, not an official index. [4]
- About 44 pharmaceutical and medical equipment companies were reported damaged or destroyed during the conflict. [6]
- Official statements differ. The Food and Drug Administration says strategic reserves of raw materials and finished medicines are in good condition and that hospital supply has no significant shortage, while noting that import routes have become slower and more expensive. [5]
5. Payments and working capital
Late payment is now a structural problem across the chain. The head of the Food and Drug Administration said in November that many hospitals have not paid their pharmaceutical suppliers for more than a year. [5] Iranian media have put insurers' debts to pharmacies at about 8 quadrillion rials, roughly 3.6 billion US dollars at the time of reporting. [6] For producers, this means more borrowing at high local interest rates to fund the gap between paying for inputs and getting paid for sales.
6. Risks
- Currency: further moves of products from the subsidised to the commercial rate, without matching price approvals.
- Pricing: delays between cost increases and official price approvals.
- Supply chain: longer and more expensive import routes for raw materials and equipment.
- Liquidity: unpaid receivables from hospitals and insurers, and the cost of financing them.
- Physical: damage to production and distribution sites, and the time needed to rebuild.
- Data: official and industry figures often differ, and some are not published regularly.
7. What to watch
- Any decision on the subsidised medicine rate in the 1406 budget, due early in 2027.
- Which product groups move to the commercial rate next, after imported insulin.
- New price approvals from the Food and Drug Administration, and how quickly they follow cost changes.
- Monthly sales reports of listed producers: whether nominal growth keeps pace with inflation.
- Settlement of hospital and insurer debts to the industry.
Sources
- EcoIran, "Currency and medicine in Iran: from hidden inflation to supply disruption risk", 9 February 2026 (in Persian). ecoiran.com
- Mehr News Agency, citing Farhad Habibi, deputy head of Iran's Food and Drug Administration, 8 November 2026 (in Persian). mehrnews.com
- EcoIran, remarks by Mahdi Pirsalehi, head of Iran's Food and Drug Administration, 24 August 2026 (in Persian). ecoiran.com
- NIAC, "Iran's Drug Costs Rise as the Rial Falls and the Blockade Strains Supply", 9 September 2026. niacouncil.org
- Shahrara News, remarks by the head of Iran's Food and Drug Administration, 3 November 2026 (in Persian). shahraranews.ir
- Al Jazeera, "Medicine shortages grow in Iran as US tightens sanctions, blockade", 9 September 2026. aljazeera.com
This brief is research and analysis only. It does not name or assess any listed company, and it is not investment advice or a recommendation to buy or sell any security. Figures are taken from the sources listed; where sources differ, both views are shown. Iranian-year dates are converted to the Gregorian calendar.
Want a brief like this on another Iranian industry? Message @dapezsolution on X.